Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells

Free Radical Biology and Medicine

Volumn 53, Issue 10, 2012, Pages 1857-1867

  Ribeiro, Márcio ^a   Rosenstock, Tatiana R ^a   Cunha Oliveira, Teresa ^a   Ferreira, Ildete L ^a   Oliveira, Catarina R ^a,b   Rego, A Cristina ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Huntingtin; Huntington disease; Oxidative stress; Reactive oxygen species; Striatal cells

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE SYNTHASE; GLUTATHIONE TRANSFERASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LEVEL; CELL MUTANT; ENZYME ACTIVITY; GLUTATHIONE METABOLISM; HUNTINGTON CHOREA; MOUSE; NERVE CELL; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRIATAL CELL; WILD TYPE;

ANIMALS; BIOLOGICAL TRANSPORT; CASPASE 3; CELLS, CULTURED; CORPUS STRIATUM; GAMMA-GLUTAMYLTRANSFERASE; GENE KNOCK-IN TECHNIQUES; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE SYNTHASE; GLUTATHIONE TRANSFERASE; HUNTINGTON DISEASE; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; NEOSTRIATUM; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER;

MUS;

EID: 84867380632     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.09.004     Document Type: Article

References (46)

1. J.M. Gil, and A.C. Rego Mechanisms of neurodegeneration in Huntington's disease Eur. J. Neurosci 27 2008 2803 2820 [Erratum: Eur. J. Neurosci. 28:2156; 2008.]
2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983; 1993.
3. R.J. Ferrante, N.W. Kowall, M.F. Beal, J.B. Martin, E.D. Bird, and E.P. Jr. Richardson Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease J. Neuropathol. Exp. Neurol. 46 1987 12 27
4. S.E. Browne, A.C. Bowling, U. MacGarvey, M.J. Baik, S.C. Berger, M.M. Muqit, E.D. Bird, and M.F. Beal Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia Ann. Neurol. 41 1997 646 653
5. S.E. Browne, R.J. Ferrante, and M.F. Beal Oxidative stress in Huntington's disease Brain Pathol. 9 1999 147 163
6. N. Stoy, G.M. Mackay, C.M. Forrest, J. Christofides, M. Egerton, T.W. Stone, and L.G. Darlington Tryptophan metabolism and oxidative stress in patients with Huntington's disease J. Neurochem. 93 2005 611 623
7. A. Goswami, P. Dikshit, A. Mishra, S. Mulherkar, N. Nukina, and N.R. Jana Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction Biochem. Biophys. Res. Commun. 342 2006 184 190
8. C.M. Chen, Y.R. Wu, M.L. Cheng, J.L. Liu, Y.M. Lee, P.W. Lee, B.W. Soong, and D.T. Chiu Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients Biochem. Biophys. Res. Communun 359 2007 335 340
9. A.V. Panov, C.A. Gutekunst, B.R. Leavitt, M.R. Hayden, J.R. Burke, W.J. Strittmatter, and J.T. Greenamyre Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines Nat. Neurosci. 5 2002 731 736
10. M.C. Polidori, P. Mecocci, S.E. Browne, U. Senin, and M.F. Beal Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex Neurosci. Lett. 272 1999 53 56
11. S.M. Hersch, S. Gevorkian, K. Marder, C. Moskowitz, A. Feigin, M. Cox, P. Como, C. Zimmerman, M. Lin, L. Zhang, A.M. Ulug, M.F. Beal, W. Matson, M. Bogdanov, E. Ebbel, A. Zaleta, Y. Kaneko, B. Jenkins, N. Hevelone, H. Zhang, H. Yu, D. Schoenfeld, R. Ferrante, and H.D. Rosas Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG Neurology 66 2006 250 252
12. M.B. Bogdanov, O.A. Andreassen, A. Dedeoglu, R.J. Ferrante, and M.F. Beal Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease J. Neurochem. 79 2001 1246 1249
13. M.A. Sorolla, G. Reverter-Branchat, J. Tamarit, I. Ferrer, J. Ros, and E. Cabiscol Proteomic and oxidative stress analysis in human brain samples of Huntington disease Free Radic. Biol. Med. 45 2008 667 678
14. D. Lim, L. Fedrizzi, M. Tartari, C. Zuccato, E. Cattaneo, M. Brini, and E. Carafoli Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease J. Biol. Chem. 283 2008 5780 5789
15. I. Tkac, J.M. Dubinsky, C.D. Keene, R. Gruetter, and W.C. Low Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy J. Neurochem. 100 2007 1397 1406
16. Y.S. Choo, Z. Mao, G.V. Johnson, and M. Lesort Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model Neurosci. Lett. 386 2005 63 68
17. F. Trettel, D. Rigamonti, P. Hilditch-Maguire, V.C. Wheeler, A.H. Sharp, F. Persichetti, E. Cattaneo, and M.E. MacDonald Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells Hum. Mol. Genet. 9 2000 2799 2809
18. C.P. LeBel, H. Ischiropoulos, and S.C. Bondy Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress Chem. Res. Toxicol. 5 1992 227 231
19. P.J. Hissin, and R. Hilf A fluorometric method for determination of oxidized and reduced glutathione in tissues Anal. Biochem. 74 1976 214 226
20. D.E. Paglia, and W.N. Valentine Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase J. Lab. Clin. Med. 70 1967 158 169
21. C.C. White, H. Viernes, C.M. Krejsa, D. Botta, and T.J. Kavanagh Fluorescence-based microtiter plate assay for glutamate-cysteine ligase activity Anal. Biochem. 318 2003 175 180
22. Y. Zhu, P.M. Carvey, and Z. Ling Age-related changes in glutathione and glutathione-related enzymes in rat brain Brain Res. 1090 2006 35 44
23. A.L. Dogan, O. Legrand, AM. Faussat, JY. Perrot, and JP. Marie Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines Leuk. Res. 28 2004 619 622
24. M. Whiteman, P. Rose, J.L. Siau, N.S. Cheung, G.S. Tan, B. Halliwell, and J.S. Armstrong Hypochlorous acid-mediated mitochondrial dysfunction and apoptosis in human hepatoma HepG2 and human fetal liver cells: role of mitochondrial permeability transition Free Radic. Biol. Med. 38 2005 1571 1584
25. M. Müller, C. Meijer, G.J. Zaman, P. Borst, R.J. Scheper, N.H. Mulder, E.G. de Vries, and P.L. Jansen Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport Proc. Natl. Acad. Sci. USA 91 1994 13033 13037
26. F. Perez-Severiano, A. Santamaria, J. Pedraza-Chaverri, O.N. Medina-Campos, and C. Rios Segovia, J. Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation Neurochem. Res. 29 2004 729 733
27. T. Milakovic, and G.V. Johnson Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin J. Biol. Chem. 280 2005 30773 30782
28. 2 handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors J. Neurosci. 26 2006 11174 11186
29. R.A. Quintanilla, Y.N. Jin, K. Fuenzalida, M. Bronfman, and G.V. Johnson Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease J. Biol. Chem. 283 2008 25628 25637
30. I. Tunez, R. Drucker-Colin, I. Jimena, F.J. Medina, C. Munoz Mdel, J. Pena, and P. Montilla Transcranial magnetic stimulation attenuates cell loss and oxidative damage in the striatum induced in the 3-nitropropionic model of Huntington's disease J. Neurochem. 97 2006 619 630
31. T.R. Rosenstock, O.M. de Brito, V. Lombardi, S. Louros, M. Ribeiro, S. Almeida, I.L. Ferreira, C.R. Oliveira, and A.C. Rego FK506 ameliorates cell death features in Huntington's disease striatal cell models Neurochem. Int. 59 2011 600 609
32. Z. Mao, Y.S. Choo, and M. Lesort Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells Eur. J. Neurosci 23 2006 1701 1710
33. M.F. Beal, W.R. Matson, E. Storey, P. Milbury, E.A. Ryan, T. Ogawa, and E.D. Bird Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex J. Neurol. Sci. 108 1992 80 87
34. N. Klepac, M. Relja, R. Klepac, S. Hecimovic, T. Babic, and V. Trkulja Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study J. Neurol. 254 2007 1676 1683
35. J. Sian, D.T. Dexter, A.J. Lees, S. Daniel, Y. Agid, F. Javoy-Agid, P. Jenner, and C.D. Marsden Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Ann. Neurol. 36 1994 348 355
36. J.H. Fox, D.S. Barber, B. Singh, B. Zucker, M.K. Swindell, F. Norflus, R. Buzescu, R. Chopra, R.J. Ferrante, A. Kazantsev, and S.M. Hersch Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation J. Neurochem. 91 2004 413 422
37. A. Zanella, C. Izzo, G. Meola, M. Mariani, M.T. Colotti, V. Silani, G. Pellegata, and G. Scarlato Metabolic impairment and membrane abnormality in red cells from Huntington's disease J. Neurol. Sci. 47 1980 93 103
38. J. Olah, P. Klivenyi, G. Gardian, L. Vecsei, F. Orosz, G.G. Kovacs, H.V. Westerhoff, and J. Ovadi Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice FEBS J. 275 2008 4740 4755
39. G. Rappa, A. Lorico, R.A. Flavell, and A.C. Sartorelli Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins Cancer Res 57 1997 5232 5237
40. S.P. Cole, and R.G. Deeley Transport of glutathione and glutathione conjugates by MRP1 Trends Pharmacol. Sci. 27 2006 438 446
41. J.H. Cha Transcriptional dysregulation in Huntington's disease Trends Neurosci. 23 2000 387 392
42. B. Mayr, and M. Montminy Transcriptional regulation by the phosphorylation-dependent factor CREB Nat. Rev. Mol. Cell. Biol. 2 2001 599 609
43. J.S. Steffan, A. Kazantsev, O. Spasic-Boskovic, M. Greenwald, Y.Z. Zhu, H. Gohler, E.E. Wanker, G.P. Bates, D.E Housman, and L.M Thompson The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription Proc. Natl. Acad. Sci. USA 97 2000 6763 6768
44. L. Cui, H. Jeong, F. Borovecki, C.N. Parkhurst, N. Tanese, and D. Krainc Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration Cell 127 2006 59 69
45. T. Minich, J. Riemer, J.B. Schulz, P. Wielinga, J. Wijnholds, and R. Dringen The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes J. Neurochem. 97 2006 373 384
46. D. Keppler Export pumps for glutathione S-conjugates Free Radic. Biol. Med. 27 1999 985 991